AOD-9604 — 5 mg

AOD-9604 is a synthetic fragment based on the C-terminal portion of human growth hormone, commonly described as residues 177–191 with an added N-terminal tyrosine. Its development rationale was to investigate fat-metabolism effects separately from the broader growth-promoting actions of intact growth hormone. Umbrella Labs presents it using this fragment identity and emphasizes the distinction from full-length GH. It should not automatically be treated as chemically identical to every product labeled “HGH fragment 176–191.” [1]

In a primary mouse study, Heffernan and colleagues reported reduced body weight and fat mass in obese animals, together with changes in beta-3-adrenergic-receptor expression and lipolytic sensitivity. Experiments involving receptor-knockout mice suggested a more complex mechanism than simple direct activation of that receptor. [2] Human development produced a different outcome: Metabolic Pharmaceuticals’ February 2007 announcement said that its 536-participant phase 2B obesity trial did not achieve statistically significant weight-loss differences from placebo at the specified endpoints, and that development for obesity was being terminated. [3] Thus, sources discuss a fat-metabolism research concept and positive animal observations alongside a negative larger human obesity result, rather than a uniform set of findings.